Virbac : H1 2024 results: record operating margin and better than expected (positive signals). Guidance, forecasts and target price reconfirmed
>A record underlying operating margin at 21.4% - Virbac has published H1 underlying operating profit of € 150.4m (+37%). Net profit was € 94.9m (+26.9%).At end-June, net debt was € 255m (vs -€ 55m at end-2023 and -€ 52m end-H1 2023) due to the acquisitions of Sasaeah (Japan) and minority interests in Globion (India). Note that the group has obtained an easing on its syndicated debt (possible extension of the € 100m commitment).At the same time, Virbac has a...Virbac is an independent veterinary pharmaceutical laboratory. Co. develops and provides veterinarians and farmers with medicines and vaccines that improve the health of food producing animals. Co. markets a range of products designed for pets and livestock. It offers seven types of products for companion animals (Parasiticides, Immunology, Antibiotics/dermatology, Specialties, Equine, Specialized pet food and Other products), and four types of products for food producing animals (Bovine parasiticides, Bovine products (excluding parasiticides), Pig/poultry antibiotics and Other products). Co. markets its products in the ethical (veterinarian) and OTC markets.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.